Monoclonal antibody · Antagonist of SARS-CoV-2 spike protein · developed by Invivyd
Adintrevimab is a neutralizing human IgG1 monoclonal antibody that binds to the receptor-binding domain of the SARS-CoV-2 spike protein, blocking viral attachment and entry into human cells. It is studied for COVID-19 treatment and potential temporary protection against SARS-CoV-2 infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04859517 | Phase 2/3 | COVID-19 | Terminated | IVVD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19
See IVVD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IVVD catalysts and pipeline →